Welcome to our dedicated page for Alpine Immune Sc news (Ticker: ALPN), a resource for investors and traders seeking the latest updates and insights on Alpine Immune Sc stock.
Alpine Immune Sciences (ALPN) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies targeting cancer, autoimmune diseases, and inflammatory conditions. This page provides investors and researchers with timely updates on ALPN's scientific advancements, strategic partnerships, and clinical milestones.
Access verified press releases and news articles covering key developments, including clinical trial progress, regulatory updates, and collaborative research initiatives. Our curated collection ensures transparent access to essential information for evaluating ALPN's position in the immunotherapy landscape.
Explore updates on ALPN's recombinant protein-based therapies and immune synapse modulation approaches. Content spans preclinical breakthroughs, Phase 1-3 trial results, licensing agreements, and financial disclosures – all critical for understanding the company's trajectory.
Bookmark this page for streamlined tracking of ALPN's progress in developing targeted treatments for complex disorders. Regular updates provide insights into the company's scientific rigor and its potential to address unmet medical challenges through immunological innovation.
Alpine Immune Sciences (NASDAQ: ALPN) has announced a collaboration with Merck to evaluate the combination of its ALPN-202 with Merck’s KEYTRUDA in a clinical trial named NEON-2. Initiated in June 2021, this trial aims to assess the safety and efficacy of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor that has shown superior efficacy in preclinical studies. The collaboration is expected to enhance clinical insights for ALPN-202, which is also being evaluated in the ongoing NEON-1 monotherapy trial for advanced malignancies.
Alpine Immune Sciences (NASDAQ: ALPN) has announced the initiation of the Synergy Phase 2 study, marking the first patient dosed with ALPN-101 for Systemic Lupus Erythematosus (SLE). The company achieved $45 million in development milestones from a 2020 agreement with AbbVie, part of a potential $730 million in total. ALPN-101, a dual inhibitor of CD28 and ICOS pathways, shows promise based on preclinical studies. The trial, randomized and double-blind, aims to enhance therapeutic outcomes for autoimmune diseases.
Alpine Immune Sciences (NASDAQ: ALPN) announced its inclusion in the Russell 3000® Index, effective June 28, 2021. This annual reconstitution involves the top 4,000 US stocks based on market capitalization. Membership in the Russell 3000® also grants automatic inclusion in the small-cap Russell 2000® Index and associated style indexes. The company aims to develop innovative immunotherapy treatments for cancer and autoimmune diseases, supported by a strong R&D team and strategic collaborations.
Alpine Immune Sciences (NASDAQ:ALPN) presented initial data from the NEON-1 Phase 1 trial of ALPN-202 at the ASCO Virtual Annual Meeting. This first-in-human study evaluates ALPN-202, a novel CD28 costimulator and dual checkpoint inhibitor, in patients with advanced malignancies. Key findings include general tolerability of the drug, with 61% of evaluable participants showing clinical benefit. Notably, one patient with metastatic colorectal cancer achieved an unconfirmed partial response. These results encourage further development of ALPN-202.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) presented preclinical data for ALPN-303 at the EULAR Congress, highlighting its potential in treating systemic lupus erythematosus and other autoimmune diseases. The data demonstrated that ALPN-303 showed greater efficacy than existing therapies, inhibiting cytokine activity and improving pharmacokinetics. In mouse models, it significantly reduced harmful antibodies and inflammation while preserving kidney function. The company plans to initiate first-in-human studies later this year, reflecting strong interest in its therapeutic approach.
Alpine Immune Sciences (NASDAQ:ALPN) announces the appointment of Zelanna Goldberg, M.D., M.A.S., as Chief Medical Officer. Dr. Goldberg, previously a senior VP at Iovance Biotherapeutics, brings over 20 years of experience in clinical development. She will lead the clinical strategy for ALPN’s promising pipeline, which includes ALPN-101, ALPN-202, and ALPN-303. As part of her inducement, she received an option to purchase 160,000 shares, vesting over four years. This strategic hiring aims to enhance the company's capabilities in addressing cancer and autoimmune diseases.
Alpine Immune Sciences (NASDAQ:ALPN) announced an investor event on June 4, 2021, at 7:00 PM ET, aligned with the 2021 ASCO Virtual Annual Meeting. The event will feature data presentation from the NEON-1 Phase 1 trial of ALPN-202, a promising immunotherapy for advanced malignancies. Attendees can join via phone or live webcast. A replay will be available for 90 days post-event. ALPN-202 is a first-in-class treatment showing superior efficacy in preclinical studies. The company plans to initiate NEON-2, a combination study of ALPN-202 and a PD-1 inhibitor, later this year.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced an oral presentation of preclinical data on its ALPN-303 program at the EULAR European Congress of Rheumatology from June 2-5, 2021. The presentation, titled ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist, focuses on treating systemic lupus erythematosus and other B cell-related autoimmune diseases. The session is scheduled for June 2 at 4:25 PM CEST (10:25 AM EDT). ALPN-303 is designed to inhibit key cytokines involved in B cell-related diseases, offering potential therapeutic benefits to patients.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) reported its first-quarter results for 2021, highlighting progress in its clinical pipeline, including the upcoming NEON-1 clinical data update at ASCO. The company has $115.4 million in cash and reported collaboration revenue of $3.2 million, an increase from $1.1 million the previous year. Net losses rose to $10.6 million from $5.5 million. R&D expenses increased to $10.4 million due to clinical trial activities, while general and administrative expenses reached $3.3 million, reflecting growth-related costs.
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) will present data from its Phase 1 clinical trial, NEON-1, focusing on ALPN-202 monotherapy at the ASCO Virtual Annual Meeting from June 4-8, 2021. The presentation titled 'First-in-human dose escalation of ALPN-202' will provide an update on the trial results, which involve a dual checkpoint inhibitor aimed at advanced malignancies. ALPN-202 has shown promising preclinical efficacy compared to conventional checkpoint inhibitors. The company also plans to initiate NEON-2, a combination study with a PD-1 inhibitor, within the year.
